Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep M. Tabernero, Takayuki Yoshino, Allen Lee Cohn et al. · The Lancet Oncology · 2015
Cited by 949 works. doi:10.1016/s1470-2045(15)70127-0
Authors
- Josep M. Tabernero
- Takayuki Yoshino
- Allen Lee Cohn
- Radka Lordick Obermannova
- Gyorgy Bodoky
- Rocio García‐Carbonero
- Tudor–Eliade Ciuleanu
- David Craig Portnoy
- Eric Van Cutsem
- Axel F. Grothey
- Jana Prausová
- Pilar García Alfonso
- Kentaro Yamazaki
- Philip R. Clingan
- Sara Lonardi
- Tae Won Kim
- Lorinda Simms
- Shao-Chun Chang
- Federico Nasroulah
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
- EuroQol - a new facility for the measurement of health-related quality of life
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial